Study details
Enrolling now
A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis
SynAct Pharma Aps
NCT IDNCT06671054ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
240
Study length
about 1.2 years
Ages
18+
Locations
3 sites in FL, PA
What this study is about
Researchers are testing different doses of a medication called AP1189 to see if it helps with early rheumatoid arthritis. The trial will last for 456 days and involve participants who have never taken DMARDs before.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take AP1189 matching placebo
- 2.Take AP1189, 100 mg
- 3.Take AP1189, 40 mg
- +1 more
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Change in Disease Activity Score 28 (DAS28)-C-Reactive Protein (CRP)
Body systems
Immune